Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MiNK Therapeutics, Inc.INKT · Entity 52 | Director | September 01, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MiNK Therapeutics, Inc.
Report date September 01, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,404 |
Reported balance
After 2026-09-01 transaction · row 1
1 source rowRow 1 · 2026-09-01 · Grant · Acquired 1,485 · Balance 24,404 F1: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 2, 2026 14:20 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 1,485 | $10.95 | $16,260.75 |
DisclosureSEC source: 0001193125-26-379522 · ownership.xml · nonDerivative · entry 1 Behner Peter · CIK 0001851420 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,404 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:05 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 1,313 | $12.38 | $16,254.94 |
DisclosureSEC source: 0001193125-26-253466 · ownership.xml · nonDerivative · entry 2 Behner Peter · CIK 0001851420 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,919 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| March 02, 2026 Filed Jun 2, 2026 20:05 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 1,491 | $10.90 | $16,251.90 |
DisclosureSEC source: 0001193125-26-253466 · ownership.xml · nonDerivative · entry 1 Behner Peter · CIK 0001851420 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,606 F2 · price: Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:19 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantStock Option (Right to Buy) · Derivative | 5,395 | $0.00 Strike: $11.12 | $0.00 |
DisclosureSEC source: 0001193125-26-004769 · ownership.xml · derivative · entry 1 Behner Peter · CIK 0001851420 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,395 Underlying: Common Stock · 5,395 shares Expires 2036-01-02 F1 · derivative.exercise_date: Option vests on February 2, 2026, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 21:10 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 1,466 | $11.09 | $16,257.94 |
DisclosureSEC source: 0001193125-25-306680 · ownership.xml · nonDerivative · entry 1 Behner Peter · CIK 0001851420 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,115 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 20:05 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantStock Option (Right to Buy) · Derivative | 3,225 | $0.00 Strike: $15.36 | $0.00 |
DisclosureSEC source: 0001193125-25-201317 · ownership.xml · derivative · entry 1 Behner Peter · CIK 0001851420 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,225 Underlying: Common Stock · 3,225 shares Expires 2035-09-09 F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 21:26 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 1,173 | $13.86 | $16,257.78 |
DisclosureSEC source: 0000950170-25-112882 · ownership.xml · nonDerivative · entry 1 Behner Peter · CIK 0001851420 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,649 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:05 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 2,267 | $7.17 | $16,254.39 |
DisclosureSEC source: 0000950170-25-081612 · ownership.xml · nonDerivative · entry 1 Behner Peter · CIK 0001851420 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,476 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:05 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 1,849 | $8.79 | $16,252.71 |
DisclosureSEC source: 0000950170-25-033528 · ownership.xml · nonDerivative · entry 1 Behner Peter · CIK 0001851420 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,209 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| December 01, 2024 Filed Dec 3, 2024 15:38 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 20,987 | $0.73 | $15,320.51 |
DisclosureSEC source: 0000950170-24-132520 · ownership.xml · nonDerivative · entry 1 Behner Peter · CIK 0001851420 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,634 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 12:23 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 18,753 | $0.82 | $15,377.46 |
DisclosureSEC source: 0000950170-24-103749 · ownership.xml · nonDerivative · entry 1 Behner Peter · CIK 0001851420 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,234 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 18:27 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 15,454 | $0.99 | $15,299.46 |
DisclosureSEC source: 0000950170-24-069216 · ownership.xml · nonDerivative · entry 1 Behner Peter · CIK 0001851420 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,481 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 23:00 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 16,185 | $0.95 | $15,375.75 |
DisclosureSEC source: 0000950170-24-026423 · ownership.xml · nonDerivative · entry 1 Behner Peter · CIK 0001851420 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,027 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 23:05 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 14,784 | $1.04 | $15,375.36 |
DisclosureSEC source: 0000950170-23-068311 · ownership.xml · nonDerivative · entry 1 Behner Peter · CIK 0001851420 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,842 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 21:04 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 10,531 | $1.46 | $15,375.26 |
DisclosureSEC source: 0000950170-23-046777 · ownership.xml · nonDerivative · entry 1 Behner Peter · CIK 0001851420 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,058 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. F2 · balance_after: In Table 1 of the Form 4 filed on June 2, 2023, the amount of securities acquired and price (column 4) and amount of securities beneficially owned following reported transaction (column 5) were erroneously reported. On June 1, 2023, 8,542 RSUs were acquired at a price of $1.80 each, resulting in a total amount of securities beneficially owned following the reported transaction of 33,527 instead of 33,721 as erroneously reported. Read SEC document |
| June 14, 2023 Filed Jun 17, 2023 00:20 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0000899243-23-015852 · doc4.xml · derivative · entry 1 Behner Peter · CIK 0001851420 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2033-06-14 F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 23:41 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 8,736 | $1.76 | $15,375.36 |
DisclosureSEC source: 0000899243-23-014412 · doc4.xml · nonDerivative · entry 1 Behner Peter · CIK 0001851420 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,721 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 19:54 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 7,357 | $2.09 | $15,376.13 |
DisclosureSEC source: 0000899243-23-006912 · doc4.xml · nonDerivative · entry 1 Behner Peter · CIK 0001851420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,985 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:10 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 5,891 | $2.61 | $15,375.51 |
DisclosureSEC source: 0000899243-22-037646 · doc4.xml · nonDerivative · entry 1 Behner Peter · CIK 0001851420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,628 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 23:05 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 11,737 | $2.62 | $30,750.94 |
DisclosureSEC source: 0000899243-22-031530 · doc4.xml · nonDerivative · entry 1 Behner Peter · CIK 0001851420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,737 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 21:16 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0000899243-22-010708 · doc4.xml · derivative · entry 1 Behner Peter · CIK 0001851420 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-03-09 F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.